Scottsdale, Arizona–(Newsfile Corp. – March 3, 2022) – Sibannac, Inc. (OTC PINK: SNNC), a Nevada corporation (the “Company”), announced the following:
The Company has been actively researching and developing a Copper1 niacin product through its licensing agreement with the patent owner, Mitosynergy. Mitosynegy has been awarded multiple U.S. patents for molecular compounds for bioavailable coppers, namely Cuprous Nicotinic Acid. These patented compounds involve the only known bioavailable Copper 1 in the Copper 1 oxidative state. (For additional information, Patent Nos.: WO2016/037181 and 20150224112.)
Mitosynergy had previously received a No Objection Letter: #910, from the FDA, allowing the Copper compound to be marketed as an Initial New Dietary Ingredient (“IND”). Now the company is moving forward in the process of submitting a New Drug Application with the FDA. Copper, in its optimal oxidative state, could be used as a pharmaceutical and nutraceutical. The company is pursuing the use of Copper 1 niacin as an immune modulator to pursue a therapeutic claim for long-COVID and blood born microaerophilic spirochete bacteria pathogens, such as Lyme Disease.
Sibannac is developing its Copper1 product through its Campus Co. platform and will likely produce the initial run in the Company’s Scottsdale-based, FDA registered facility.
“Sibannac will be delivering best-in-class wellness products based on cutting-edge formulations. We’re working with some of the best design people in the industry and moving toward offering clinically-proven ingredients in our products,” said Sibannac’s CEO, David Mersky.
Cautionary Note Regarding Forward-Looking Statements.
This press release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Sibannac, Inc. (the “Company”), its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control, and actual results may differ materially from those projected in the forward looking statements as a result of various factors. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities.
Media Contact: [email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/115526